MEKICS CO., Ltd (058110) Fair Value & Analysis
Healthcare · KR · Market cap 31.2B KRW
Fair value as of: Jul 6, 2026
From 1 valuation models · updated today
Fair value updated Jul 6, 2026 — revised from 10,450 KRW to 1,514 KRW (−85.5%) since Jun 24, 2026. Share price −6.3% over the past month.
Price vs Fair Value (12 months)
12‑month range 1,486 KRW – 3,460 KRW · fair‑value band 1,130 KRW – 2,260 KRW · the 1,926 KRW price screens above the 1,514 KRW fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
MEKICS CO., Ltd (058110) currently trades at 1,926 KRW, while our model-based Fair Value estimate is 1,514 KRW — implying the stock looks roughly 21.4% overvalued today. We read business quality at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, MEKICS CO., Ltd generated revenue of 33.2B KRW at a net margin of 3.2%. Revenue declined 56.3% year over year. Net debt stands at 12.5B KRW. Fundamentals as of Jul 6, 2026
Our scenario range runs from 1,130 KRW (bear case) to 2,260 KRW (bull case); at 1,926 KRW, the current price sits within that range. The share trades about 52% below its 52-week high and 30% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 13% fair-value upside — at -21%, 058110 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
MEKICS CO., Ltd develops and commercializes ventilators worldwide. It offers general-purpose ventilators, respiratory care devices, patient monitoring systems, pulse oximeter, central monitoring system, and high flow nasal therapy products. The company also distributes CPAP solutions that care sleep apnea syndrome and snoring. MEKICS CO., Ltd was founded in 1998 and is headquartered in Paju, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
MEKICS CO., Ltd reported revenue of 11.3B KRW in FY2025 versus 49.3B KRW in FY2021, a compound −30.8%/yr. Reported net income was −2.5B KRW in FY2025.
Is 058110 fairly valued? → Check now
Similar stocks
10 more Healthcare Equipment & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| InBody Co 041830 | 46,200 KRW | 50,769 KRW | +10% |
| i-SENS, Inc 099190 | 15,000 KRW | 2,657 KRW | -82% |
| Value Added Technology Co 043150 | 17,800 KRW | 60,242 KRW | +238% |
| Mediana Co 041920 | 11,980 KRW | 13,550 KRW | +13% |
| Meta Biomed Co 059210 | 3,575 KRW | 9,875 KRW | +176% |
| Sewoon Medical Co 100700 | 2,220 KRW | 5,213 KRW | +135% |
| MEDIC MEDIC | 0.2000 PHP | 0.2100 PHP | +5% |
| NST NST | 0.6300 PLN | 2.03 PLN | +222% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| UnitedHealth Group UNH | 7,169 MXN | 5,226 MXN | -27% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is MEKICS CO., Ltd (058110) undervalued?
What is the fair value of 058110?
What is the quality score of 058110?
What is the revenue of MEKICS CO., Ltd (058110)?
What is the net profit margin of 058110?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.